Lexaria Eyes Growing Oral GLP-1 Market After Eli Lilly’s Foundayo Approval

Lexaria Bioscience ( (LEXX) ) has shared an announcement.

Lexaria Bioscience is highlighting the U.S. FDA’s approval of Eli Lilly’s Foundayo oral GLP-1 agonist for obesity and weight-related conditions as a catalyst for the expanding market in oral weight-loss and diabetes therapies. With only three FDA-approved oral GLP-1 brands yet multibillion-dollar and still underpenetrated global revenues, Lexaria sees growing opportunity to license its DehydraTECH formulation to major drug makers to mitigate the gastrointestinal side effects that plague GLP-1 treatments.

The company points to internal studies where DehydraTECH processing reduced adverse events, including a nearly 48% drop in total side effects versus an existing oral semaglutide product, and plans additional testing in 2026 with newer GLP-1 candidates such as retatrutide, amycretin and potentially orforglipron. By addressing tolerability issues in a fast-growing category where new oral options like Foundayo offer dosing convenience but higher reported side effects, Lexaria aims to position DehydraTECH as a competitive differentiator for stakeholders across the GLP-1 drug ecosystem.

The most recent analyst rating on (LEXX) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.

More about Lexaria Bioscience

Lexaria Bioscience Corp. is a Kelowna, British Columbia-based drug delivery technology company focused on its patented DehydraTECH platform for oral administration of pharmaceuticals. The technology is designed to enhance bio-absorption, reduce side effects and improve delivery, including across the blood-brain barrier, supported by a portfolio of 65 issued patents and additional applications worldwide.

Average Trading Volume: 182,651

Technical Sentiment Signal: Sell

Current Market Cap: $26.38M

See more data about LEXX stock on TipRanks’ Stock Analysis page.